Toronto Dominion Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.74M | Sell |
13,187
-2,696
| -17% | -$358K | ﹤0.01% | 1193 |
|
|
2025
Q4 | $2.25M | Sell |
15,883
-215
| -1% | -$31.1K | ﹤0.01% | 1088 |
|
|
2025
Q3 | $2.26M | Sell |
16,098
-1,856
| -10% | -$251K | ﹤0.01% | 1017 |
|
|
2025
Q2 | $2.26M | Buy |
17,954
+2,746
| +18% | +$315K | ﹤0.01% | 947 |
|
|
2025
Q1 | $1.68M | Buy |
15,208
+2,025
| +15% | +$257K | ﹤0.01% | 980 |
|
|
2024
Q4 | $1.8M | Buy |
13,183
+499
| +4% | +$61.7K | ﹤0.01% | 946 |
|
|
2024
Q3 | $1.46M | Buy |
12,684
+3,131
| +33% | +$429K | ﹤0.01% | 806 |
|
|
2024
Q2 | $1.32M | Sell |
9,553
-410
| -4% | -$56.2K | ﹤0.01% | 858 |
|
|
2024
Q1 | $1.37M | Sell |
9,963
-3,329
| -25% | -$455K | ﹤0.01% | 839 |
|
|
2023
Q4 | $1.75M | Sell |
13,292
-19,446
| -59% | -$2.24M | ﹤0.01% | 886 |
|
|
2023
Q3 | $3.68M | Sell |
32,738
-4,794
| -13% | -$505K | 0.01% | 759 |
|
|
2023
Q2 | $3.54M | Buy |
37,532
+10,015
| +36% | +$979K | 0.01% | 778 |
|
|
2023
Q1 | $2.78M | Sell |
27,517
-1,310
| -5% | -$136K | ﹤0.01% | 820 |
|
|
2022
Q4 | $3.44M | Buy |
28,827
+7,885
| +38% | +$924K | 0.01% | 779 |
|
|
2022
Q3 | $2.22M | Sell |
20,942
-307
| -1% | -$31.1K | ﹤0.01% | 872 |
|
|
2022
Q2 | $2.07M | Buy |
21,249
+938
| +5% | +$86.6K | ﹤0.01% | 745 |
|
|
2022
Q1 | $1.9M | Sell |
20,311
-33,350
| -62% | -$2.83M | ﹤0.01% | 797 |
|
|
2021
Q4 | $4.57M | Buy |
53,661
+40,310
| +302% | +$3.71M | 0.01% | 653 |
|
|
2021
Q3 | $1.28M | Sell |
13,351
-85
| -0.6% | -$8.03K | ﹤0.01% | 854 |
|
|
2021
Q2 | $1.31M | Buy |
13,436
+1,441
| +12% | +$138K | ﹤0.01% | 834 |
|
|
2021
Q1 | $1.17M | Sell |
11,995
-4,686
| -28% | -$491K | ﹤0.01% | 846 |
|
|
2020
Q4 | $1.6M | Buy |
16,681
+1,916
| +13% | +$185K | ﹤0.01% | 831 |
|
|
2020
Q3 | $1.42M | Buy |
14,765
+1,416
| +11% | +$164K | ﹤0.01% | 793 |
|
|
2020
Q2 | $1.63M | Buy |
13,349
+1,411
| +12% | +$156K | ﹤0.01% | 759 |
|
|
2020
Q1 | $1.03M | Sell |
11,938
-3,293
| -22% | -$322K | ﹤0.01% | 755 |
|
|
2019
Q4 | $1.64M | Buy |
+15,231
| New | +$1.59M | ﹤0.01% | 800 |
|
|
2019
Q1 | – | Sell |
-13
| Closed | -$1K | – | 1680 |
|
|
2018
Q4 | $1K | Buy |
13
+8
| +160% | +$766 | ﹤0.01% | 1432 |
|
|
2018
Q3 | $1K | Sell |
5
-7,585
| -100% | -$861K | ﹤0.01% | 1330 |
|
|
2018
Q2 | $746K | Buy |
7,590
+7,560
| +25,200% | +$677K | ﹤0.01% | 966 |
|
|
2018
Q1 | $2K | Buy |
+30
| New | +$2.53K | ﹤0.01% | 1247 |
|
Other funds holding NBIX
VPM
VCM
Toronto Dominion Bank's NBIX Position: Q1 2026 in Review
Toronto Dominion Bank reduced its Neurocrine Biosciences (NBIX) stake by 17% in Q1 2026, selling an estimated $358K and leaving 13,187 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1193.
Toronto Dominion Bank first reported a position in NBIX in Q1 2018 and has held it in 30 quarters since. The position peaked at $4.57M in Q4 2021. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Toronto Dominion Bank held 13,187 shares of Neurocrine Biosciences worth $1.74M as of Q1 2026.
- Toronto Dominion Bank sold 2,696 Neurocrine Biosciences shares in Q1 2026, an estimated $358K.
- Neurocrine Biosciences made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #1193 holding.
- Toronto Dominion Bank first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 30 quarters since.
- Toronto Dominion Bank's Neurocrine Biosciences position peaked at $4.57M in Q4 2021.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.